500
0
0

November is Lung Cancer Awareness Month. Explore both sides of lung cancer diagnosis →

Skip to Content
Lung Cancer Europe | Advocacy and Access for Lung Cancer in Europe
🔍
Overview
Contact
Our Board
Newsletter
Brand hub
Our Partners
Supporters & Funding
Annual Reports
SCLC Report
Policy and resources
English
Our Members
Lung Cancer Europe | Advocacy and Access for Lung Cancer in Europe
🔍
Overview
Contact
Our Board
Newsletter
Brand hub
Our Partners
Supporters & Funding
Annual Reports
SCLC Report
Policy and resources
English
Our Members
🔍
Folder: Who We Are
Back
Overview
Contact
Our Board
Newsletter
Brand hub
Our Partners
Supporters & Funding
Folder: Reports
Back
Annual Reports
SCLC Report
Policy and resources
English
Back
Our Members
No results found
Treatment and research Web Team 01/07/2026 Treatment and research Web Team 01/07/2026

HARMONi-7: European sites now open for Phase 3 ivonescimab trial in high PD-L1 NSCLC

Read More

With Thanks to Our Supporters

Lung Cancer Europe is grateful to the partners who share our commitment to people affected by lung cancer. Their support helps us turn our mission into action across research, education and advocacy.

Accord Healthcare Amgen Bayer AstraZeneca BeOne Medicines BioNTech Blueprint Medicines Bristol Myers Squibb Boehringer Ingelheim Daiichi Sankyo Genmab Gilead Johnson & Johnson Lilly Merck Group MSD Novartis Novocure Pfizer PharmaCosmos PharmaMar Pierre Fabre Regeneron Roche Takeda Thermo Fisher

Connect with us on LinkedIn

Stay in the loop

You can subscribe to updates from Lung Cancer Europe by signing up to our monthly newsletter below. Our newsletter goes out on the 1st of every month and we also send out news bulletins and updates.

By signing up, you agree to receive emails from Lung Cancer Europe. You can unsubscribe at any time. Read our Privacy Policy to learn how we handle your data.

PRIVACY POLICY
COMPLIANCE

© Lung Cancer Europe 2026 | Designed by Laura Jones